tetradecahydro-phenazine | 60514-57-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: tetradecahydro-phenazine
• 英文别名: Tetradecahydro-phenazin；Perhydrophenazine；1,2,3,4,4a,5,5a,6,7,8,9,9a,10,10a-tetradecahydrophenazine
• CAS: 60514-57-0
• 化学式: C₁₂H₂₂N₂
• mdl: MFCD06637645
• 分子量: 194.32
• InChiKey: JPOVEXSHVNWPRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  cis-1,2,3,4,4a,5,10,10a-octahydrophenazine 在 镍 作用下， 生成 tetradecahydro-phenazine
  参考文献：
  名称：

  378.吩嗪系列。第四部分 八氢和全氢吩嗪

  摘要：

  DOI：

  10.1039/jr9360001698

文献信息

• TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR
  申请人：Seikagaku Corporation

  公开号：US20200138964A1

  公开（公告）日：2020-05-07

  Provided is a compound obtained by conjugating a tertiary amine compound or imine compound, which is useful as a drug, with a polymer, in which a structure D + having a quaternary ammonium salt or iminium salt formed from a tertiary amine compound or imine compound D and a polymer residue Poly having a carboxy group are bonded to each other via a structure —C(R 1 )(R 2 )OC(O)ANHC(═O)—.

  提供的是一种化合物，通过将一种三级胺化合物或亚胺化合物与聚合物共轭，用作药物，其中具有由三级胺化合物或亚胺化合物D形成的季铵盐或亚胺盐的结构D + 和具有羧基的聚合物残基Poly通过结构—C(R 1 )(R 2 )OC(O)ANHC(═O)—相互键合。
• Biocatalytic Access to Piperazines from Diamines and Dicarbonyls
  作者：Niels Borlinghaus、Sebastian Gergel、Bettina M. Nestl

  DOI：10.1021/acscatal.8b00291

  日期：2018.4.6

  Given the widespread importance of piperazines as building blocks for the production of pharmaceuticals, an efficient and selective synthesis is highly desirable. Here we show the direct synthesis of piperazines from 1,2-dicarbonyl and 1,2-diamine substrates using the R-selective imine reductase from Myxococcus stipitatus as biocatalyst. Various N- and C-substituted piperazines with high activity and excellent

  考虑到哌嗪作为生产药物的基础材料的广泛重要性，非常需要有效和选择性的合成。在这里，我们显示了使用来自粘球菌的R-选择性亚胺还原酶作为生物催化剂，从1,2-二羰基和1,2-二胺底物直接合成哌嗪的方法。在温和的反应条件下获得了高达每升8.1克的各种具有高活性和优异对映选择性的N和C取代的哌嗪。
• [EN] IMMUNOCONJUGATES TARGETING PD-L1<br/>[FR] IMMUNOCONJUGUÉS CIBLANT LE PD-L1
  申请人：BOLT BIOTHERAPEUTICS INC

  公开号：WO2020190734A1

  公开（公告）日：2020-09-24

  The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

  该发明提供了公式（I）或（II）的免疫结合物。该发明的抗体-佐剂免疫结合物包括一个抗体构造，其具有结合程序性死亡配体1（PD-L1）的抗原结合结构域，与一个或多个佐剂连接，表现出比传统抗体结合物更优越的药理特性。该发明还提供了包含该免疫结合物的组合物和治疗癌症的方法。
• [EN] IMMUNOCONJUGATES TARGETING CEA<br/>[FR] IMMUNOCONJUGUÉS CIBLANT L'ACE
  申请人：BOLT BIOTHERAPEUTICS INC

  公开号：WO2020190760A1

  公开（公告）日：2020-09-24

  The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen ("CEA") linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

  该发明提供了式（I）或（II）的免疫结合物。该发明的抗体-佐剂免疫结合物包括一个抗体构建物，其具有结合癌胚抗原（“CEA”）的抗原结合结构域，与一个或多个佐剂连接，表现出比传统抗体结合物更优越的药理特性。该发明还提供了包含该免疫结合物的组合物和治疗癌症的方法。
• [EN] IMMUNOCONJUGATES TARGETING HER2<br/>[FR] IMMUNOCONJUGUÉS CIBLANT LE HER2
  申请人：BOLT BIOTHERAPEUTICS INC

  公开号：WO2020190731A1

  公开（公告）日：2020-09-24

  The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor 2 ("HER2") linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

  该发明提供了公式(I)或(II)的免疫结合物。该发明的抗体-佐剂免疫结合物包括一个抗体构建物，具有结合人类表皮生长因子受体2（"HER2"）的抗原结合结构域，与一个或多个佐剂相连，展示出比传统抗体结合物更优越的药理特性。该发明还提供了包含该免疫结合物的组合物和用于治疗癌症的方法。